07:33 AM EDT, 03/18/2025 (MT Newswires) -- Prime Medicine ( PRME ) said Tuesday it has launched a preclinical program for the treatment of alpha-1 antitrypsin deficiency as part of its liver treatment business.

The company said it plans to file an investigational new drug application and/or clinical trial application in mid-2026.

Chief Executive Officer and President Keith Gottesdiener said in vivo data from its preclinical trial "reinforce the potential of Prime Editing to restore the disease-causing mutation back to wild-type."